Cargando…

The role of post-operative radiotherapy in non-small-cell lung cancer: a multicentre randomised trial in patients with pathologically staged T1-2, N1-2, M0 disease. Medical Research Council Lung Cancer Working Party.

The role of post-operative radiotherapy for patients with non-small-cell lung cancer (NSCLC) is unclear despite five previous randomised trials. One deficiency with these trials was that they did not include adequate TNM staging, and so the present randomised trial was designed to compare surgery al...

Descripción completa

Detalles Bibliográficos
Autores principales: Stephens, R. J., Girling, D. J., Bleehen, N. M., Moghissi, K., Yosef, H. M., Machin, D.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1996
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074683/
https://www.ncbi.nlm.nih.gov/pubmed/8761382
_version_ 1782138019069820928
author Stephens, R. J.
Girling, D. J.
Bleehen, N. M.
Moghissi, K.
Yosef, H. M.
Machin, D.
author_facet Stephens, R. J.
Girling, D. J.
Bleehen, N. M.
Moghissi, K.
Yosef, H. M.
Machin, D.
author_sort Stephens, R. J.
collection PubMed
description The role of post-operative radiotherapy for patients with non-small-cell lung cancer (NSCLC) is unclear despite five previous randomised trials. One deficiency with these trials was that they did not include adequate TNM staging, and so the present randomised trial was designed to compare surgery alone (S) with surgery plus post-operative radiotherapy (SR) in patients with pathologically staged T1-2, N1-2. M0 NSCLC. Between July 1986 and October 1993, 308 patients (154 S, 154 SR) were entered from 16 centres in the UK. The median age of the patients was 62 years, 74% were male, > 85% had normal or near normal levels of general condition, activity and breathlessness, 68% had squamous carcinoma, 52% had had a pneumonectomy, 63% had N1 disease and 37% N2 disease. SR patients received 40 Gy in 15 fractions starting 4-6 weeks post-operatively. Overall there was no advantage to either group in terms of survival, although definite local recurrence and bony metastases appeared less frequently and later in the SR group. In a subgroup analysis, in the N1 group no differences between the treatment groups were seen, but in the N2 group SR patients appeared to gain a one month survival advantage, delayed time to local recurrence and time to appearance of the bone metastases. There is, therefore, no clear indication for post-operative radiotherapy in N1 disease, but the question remains unresolved in N2 disease.
format Text
id pubmed-2074683
institution National Center for Biotechnology Information
language English
publishDate 1996
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-20746832009-09-10 The role of post-operative radiotherapy in non-small-cell lung cancer: a multicentre randomised trial in patients with pathologically staged T1-2, N1-2, M0 disease. Medical Research Council Lung Cancer Working Party. Stephens, R. J. Girling, D. J. Bleehen, N. M. Moghissi, K. Yosef, H. M. Machin, D. Br J Cancer Research Article The role of post-operative radiotherapy for patients with non-small-cell lung cancer (NSCLC) is unclear despite five previous randomised trials. One deficiency with these trials was that they did not include adequate TNM staging, and so the present randomised trial was designed to compare surgery alone (S) with surgery plus post-operative radiotherapy (SR) in patients with pathologically staged T1-2, N1-2. M0 NSCLC. Between July 1986 and October 1993, 308 patients (154 S, 154 SR) were entered from 16 centres in the UK. The median age of the patients was 62 years, 74% were male, > 85% had normal or near normal levels of general condition, activity and breathlessness, 68% had squamous carcinoma, 52% had had a pneumonectomy, 63% had N1 disease and 37% N2 disease. SR patients received 40 Gy in 15 fractions starting 4-6 weeks post-operatively. Overall there was no advantage to either group in terms of survival, although definite local recurrence and bony metastases appeared less frequently and later in the SR group. In a subgroup analysis, in the N1 group no differences between the treatment groups were seen, but in the N2 group SR patients appeared to gain a one month survival advantage, delayed time to local recurrence and time to appearance of the bone metastases. There is, therefore, no clear indication for post-operative radiotherapy in N1 disease, but the question remains unresolved in N2 disease. Nature Publishing Group 1996-08 /pmc/articles/PMC2074683/ /pubmed/8761382 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Stephens, R. J.
Girling, D. J.
Bleehen, N. M.
Moghissi, K.
Yosef, H. M.
Machin, D.
The role of post-operative radiotherapy in non-small-cell lung cancer: a multicentre randomised trial in patients with pathologically staged T1-2, N1-2, M0 disease. Medical Research Council Lung Cancer Working Party.
title The role of post-operative radiotherapy in non-small-cell lung cancer: a multicentre randomised trial in patients with pathologically staged T1-2, N1-2, M0 disease. Medical Research Council Lung Cancer Working Party.
title_full The role of post-operative radiotherapy in non-small-cell lung cancer: a multicentre randomised trial in patients with pathologically staged T1-2, N1-2, M0 disease. Medical Research Council Lung Cancer Working Party.
title_fullStr The role of post-operative radiotherapy in non-small-cell lung cancer: a multicentre randomised trial in patients with pathologically staged T1-2, N1-2, M0 disease. Medical Research Council Lung Cancer Working Party.
title_full_unstemmed The role of post-operative radiotherapy in non-small-cell lung cancer: a multicentre randomised trial in patients with pathologically staged T1-2, N1-2, M0 disease. Medical Research Council Lung Cancer Working Party.
title_short The role of post-operative radiotherapy in non-small-cell lung cancer: a multicentre randomised trial in patients with pathologically staged T1-2, N1-2, M0 disease. Medical Research Council Lung Cancer Working Party.
title_sort role of post-operative radiotherapy in non-small-cell lung cancer: a multicentre randomised trial in patients with pathologically staged t1-2, n1-2, m0 disease. medical research council lung cancer working party.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074683/
https://www.ncbi.nlm.nih.gov/pubmed/8761382
work_keys_str_mv AT stephensrj theroleofpostoperativeradiotherapyinnonsmallcelllungcanceramulticentrerandomisedtrialinpatientswithpathologicallystagedt12n12m0diseasemedicalresearchcouncillungcancerworkingparty
AT girlingdj theroleofpostoperativeradiotherapyinnonsmallcelllungcanceramulticentrerandomisedtrialinpatientswithpathologicallystagedt12n12m0diseasemedicalresearchcouncillungcancerworkingparty
AT bleehennm theroleofpostoperativeradiotherapyinnonsmallcelllungcanceramulticentrerandomisedtrialinpatientswithpathologicallystagedt12n12m0diseasemedicalresearchcouncillungcancerworkingparty
AT moghissik theroleofpostoperativeradiotherapyinnonsmallcelllungcanceramulticentrerandomisedtrialinpatientswithpathologicallystagedt12n12m0diseasemedicalresearchcouncillungcancerworkingparty
AT yosefhm theroleofpostoperativeradiotherapyinnonsmallcelllungcanceramulticentrerandomisedtrialinpatientswithpathologicallystagedt12n12m0diseasemedicalresearchcouncillungcancerworkingparty
AT machind theroleofpostoperativeradiotherapyinnonsmallcelllungcanceramulticentrerandomisedtrialinpatientswithpathologicallystagedt12n12m0diseasemedicalresearchcouncillungcancerworkingparty
AT stephensrj roleofpostoperativeradiotherapyinnonsmallcelllungcanceramulticentrerandomisedtrialinpatientswithpathologicallystagedt12n12m0diseasemedicalresearchcouncillungcancerworkingparty
AT girlingdj roleofpostoperativeradiotherapyinnonsmallcelllungcanceramulticentrerandomisedtrialinpatientswithpathologicallystagedt12n12m0diseasemedicalresearchcouncillungcancerworkingparty
AT bleehennm roleofpostoperativeradiotherapyinnonsmallcelllungcanceramulticentrerandomisedtrialinpatientswithpathologicallystagedt12n12m0diseasemedicalresearchcouncillungcancerworkingparty
AT moghissik roleofpostoperativeradiotherapyinnonsmallcelllungcanceramulticentrerandomisedtrialinpatientswithpathologicallystagedt12n12m0diseasemedicalresearchcouncillungcancerworkingparty
AT yosefhm roleofpostoperativeradiotherapyinnonsmallcelllungcanceramulticentrerandomisedtrialinpatientswithpathologicallystagedt12n12m0diseasemedicalresearchcouncillungcancerworkingparty
AT machind roleofpostoperativeradiotherapyinnonsmallcelllungcanceramulticentrerandomisedtrialinpatientswithpathologicallystagedt12n12m0diseasemedicalresearchcouncillungcancerworkingparty